Leerink Partners Sticks to Their Buy Rating for Rhythm Pharmaceuticals (RYTM)
I'm PortAI, I can summarize articles.
Leerink Partners analyst Faisal Khurshid maintained a Buy rating for Rhythm Pharmaceuticals with a price target of $142.00. Khurshid, who covers the Healthcare sector, has a 55.8% average return and a 59.02% success rate on recommended stocks. Rhythm Pharmaceuticals also received a Buy rating from Morgan Stanley, while TR reiterated a Hold rating.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments